// App-Quantinova.ai

POS0901 (2021) : IXEKIZUMAB SHOWS A DISTINCT PATTERN OF PAIN IMPROVEMENT BEYOND INFLAMMATION IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

Researchers

Presenter

  • K. De Vlam

Principal Investigators

  • G. Gallo

  • P. J. Mease

  • P. Rahman

  • V. Krishnan

  • D. Sandoval

  • C. Y. Lin

  • R. Bolce

  • P. G. Conaghan

Medical Centers

  • University Hospital CHU of Liege, Gastroenterology, Liege, Belgium

  • Eli Lilly and Company Corporate Center, Statistics, Indianapolis, United States of America

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • Memorial University of Newfoundland, St. John's, NF, Canada

  • University of Sheffield School of Medicine, Sheffield, United Kingdom

Locations

  • Belgium

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02696785

Sponsors

  • Celgene

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved